An Open-label Single-arm Multicentre Non-controlled Phase 3a Trial Investigating Safety and Efficacy of N8-GP in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Paediatric Patients With Severe Haemophilia A
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Pharmacodynamics; Registrational
- Acronyms pathfinder6
- Sponsors Novo Nordisk
- 07 Jun 2017 Biomarkers information updated
- 25 May 2016 The trial was restarted in Germany.
- 12 May 2016 The trial is suspended in Germany as per European Clinical Trials Database record.